References

porozendo

Остеопороз и остеопатии

Osteoporosis and Bone Diseases

2072-26802311-0716

Endocrinology Research Centre

10.14341/osteo2007331-35

porozendo-4124

Research Article

Статьи

Articles

ИЗУЧЕНИЕ ПЕРЕНОСИМОСТИ АЛЕНДРОНАТА 70 МГ (ФОСАМАКС 70 МГ ОДИН РАЗ В НЕДЕЛЮ) И ПРИЧИНОТМЕНЫ ЛЕЧЕНИЯ У БОЛЬНЫХ ПОСТМЕНОПАУЗАЛЬНЫМОСТЕОПОРОЗОМ В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙПРАКТИКИ

IZUChENIE PERENOSIMOSTI ALENDRONATA 70 MG (FOSAMAKS 70 MG ODIN RAZ V NEDELYu) I PRIChINOTMENY LEChENIYa U BOL'NYKh POSTMENOPAUZAL'NYMOSTEOPOROZOM V USLOVIYaKh REAL'NOY KLINIChESKOYPRAKTIKI

LYaLINA

V V

MYLOV

N M

DMITRIEVA

E G

KORVYaKOV

E L

2007

15122007

103

№3 (2007)

3135

2007

LYaLINA V.V., MYLOV N.M., DMITRIEVA E.G., KORVYaKOV E.L.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.osteo-endojournals.ru/jour/article/view/4124

Проведено проспективное, открытое неконтролируемое исследование переносимости алендроната 70 мг в неделю и причин отмены лечения в условиях реальной клинической практики. Работа основана на результатах годичного наблюдения 427 пациенток (67+8,2 года) с установленным диагнозом постменопаузального остеопороза, которым было назначено лечение алендронатом 70 мг в неделю. Наряду с остеопорозом, 64% исследуемых имели в анамнезе хронические заболевания ЖКТ, а 36% пациенток помимо алендроната получали многочисленные другие препараты. В течение года наблюдения около 30% пациенток прекратили принимать алендронат. Наиболее часто отмена лечения происходила (% исследуемых; % причин) по финансовым причинам (20%; 68%), а также вследствие обострений хронических заболеваний ЖКТ (9%; 29,6%). Связь обострений с приемом алендроната не установлена. Отмечено 3 случая достоверной непереносимости алендроната 70 мг (0,7%; 2,3%). У пациентов, непрерывно продолжавших лечение в течение года, отмечена хорошая переносимость алендроната вне зависимости от наличия заболеваний ЖКТ (p=0,953); в 22% случаев наблюдались незначительные проявления диспепсии, связь которых с приемом алендроната не доказана. При проведении терапии алендронатом 70 мг наиболее сложной клинической задачей является интерпретация нежелательных явлений. Необходимо дифференцировать побочные эффекты алендроната от проявлений фоновых заболеваний ЖКТ и негативных эффектов других медикаментов.

The aim of study was tolerability and causes of discontinuation to alendronate 70 mg OW therapy in nonresearch real world setting. We prospectively analyzed 427 female patients (67+8,2years) newly prescribed with alendronate 70mg OW for postmenopausal osteoporosis and followed up during a year. The background of GI diseases was reported in 64% of patients, while 36% were receiving three or more concomitant medications. 30% of patients discontinued therapy throughout the year. The most frequent reasons for treatment discontinuation were unaffordable price of alendronate (20% of all patients; 68% of all discontinuation cases) and GI complaints (9%;29,6%), despite most cases were not assumed to be related to the drug. There were only 3 cases of intolerance to alendronate (0,7%;2,3%). In persistent patients alendornate was overall well tolerated; in 22% of them minor or mild dyspepsia was reported. The incidence of dyspepsia was not associated with the presence of GI diseases (p=0,953). The study suggests that a large proportion of GI adverse experiences seen on aledronate treatment may not have causal relationship to therapy. The high rate of GI diseases and concomitant drugs in osteoporosis patients are underestimated in clinical practice.

References1

Дедов И.И., Рожинская Л.Я., Белая Ж.Е. «Роль и место бисфофонатов в профилактике и лечении остеопороза.10-летний опыт применения алендроната (Фосамакса). Обзор литературы». Остеопороз и остеопатии, 2005, № 1, стр. 20-30.

Древаль А.В., Марченкова Л.А., Крюкова И.В. и соавт. «Эффективность, переносимость и комплаентность алендронат натрия (70 мг 1 раз в неделю) при лечении постменопаузального остеопороза». Остеопороз и остеопатии 2006, № 2, стр 13-17.

Клинические рекомендации. Гастроэнтерология / под ред. В.Т. Ивашкина - М.: ГЭОТАР-Медиа 2006. - стр. 30-35.

Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение / под ред. Л.И. Беневоленской, О.М. Лесняк - М.: ГЭОТАР-Медиа, 2005. - стр. 66-72.

Aki S., Eskiyurt N., et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J. 2003 Dec 30;44 (6):961-7

Amagase K., Hayashi S., Nishikawa K., et al. Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig Dis Sci. 2007 Aug;52 (8):1879-89. Epub 2007 Apr 5

Anastasilakis A.D., Goulis D.G., Kita M., Avramidis A. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens). 2007 Jul-Sep;6 (3):233-41.

Bartl R., Götte S., Hadji P., Hammerschmidt T. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment] Dtsch Med Wochenschr. 2006 Jun 2;131 (22):1257-62.

Bauer D.C., Black D., Ensrud K. et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160: 517-25.

Blouin J., Dragomir A., Ste-Marie L.G., et al. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002- 2004 among osteoporotic women. J Clin Endocrinol Metab. 2007 Mar; 92 (3):887-94.

Bonnick S,. Saag K.G., Kiel D.P., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul; 91 (7):2631-7.

Briesacher B.A., Andrade S.E., Yood R.A., Kahler K.H. Consequences of poor compliance with bisphosphonates. Bone. 2007 Jul 18; [Epub ahead of print]

Briot K., Tremollieres F., Thomas T., Roux C.; How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine. 2007 Jan;74 (1):24-31.

Brookhart M.A., Avorn J., Katz J.N., et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007 Mar;120 (3):251-6.

Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006, 368:2005-2006

Cooper A., Drake J., Brankin E., et al. Treatment persistence with once-monthly ibandronate and patient support vs. once weekly alendronate: results from the PERSIST study. J Clin Practice, 2006, 60:896-905

Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005 Sep;21 (9):1453-60.

Cramer J.A., Lynch N.O., Gaudin A.F., et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006 Oct;28 (10):1686-94.

Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C., et al. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23: 570-8.

Cryer B., Bauer D.C. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77: 1031-43.

Cryer B., Binkley N., Simonelli C. et al. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am О Geriatr Pharmacother, 2005, Sep; 3 (3): 127-36.

Cryer B., Miller P., Petruschke R.A. et al. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005 Mar 1;21 (5):599-607.

Downey T.W., Foltz S.H., Boccuzzi S.J., et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006 Jun;99 (6):570-5.

Eisman J.A., Rizzoli R., et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2004 May;20 (5):699-705.

Emkey R.D., Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med, 2006, 119:S18-S24

Fardellone P., Gaudin A.F., Cotte F.E. Comparison of the persistence of daily and weekly bisphosphonates in female patients treated for osteoporosis. J Bone Miner Res, 2005, 20 (Suppl 1):S285-S286

Gold D.T., Alexander I.M., Ettinger M.P. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 2006 Jun;40 (6):1143-50.

Goldstein J.L., Eisen G.M., Lewis B., et al. Video capsule endoscopy to prospectively access small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol., 2005;3:133- 141.

Graham D.Y., Malaty H.M. Alendronate and naproxen are synergistic for development of gastric ulcers Arch Intern Med., 2001, Jan 8;161 (1):107-10.

Greenspan S., Field-Munves E., et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002 Oct;77 (10):1044-52.

Heras Rincón I., Zubillaga Rodriguez I., et al. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal. 2007 Aug 1;12 (4):E267-71.

Ho A.Y., Kung A.W. Efficacy and tolerability of alendronate once weekly inAsian postmenopausal osteoporotic women. Ann Pharmacother. 2005 Sep;39 (9):1428-33.

ICSI Health Care Guidline: Diagnosis and Treatment of Osteoporosis, Fifth Edition, July 2006. www.icsi.org <http://www.icsi.org>.

Ideguchi H., Ohno S., Hattori H., Ishigatsubo Y. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int, 2007, 18:1421-1427.

Iwamoto J., Takeda T., Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin. 2006 May;22 (5):919-28.

Khapra A.P., Rose S. Drug injury in the upper gastrointestinal tract: effects of alendronate. Gastrointest Endosc Clin N Am. 2006 Jan;16 (1):99-110.

Lanza F., Rack M.F., et al. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol. 1998 May;93 (5):753-7.

Lanza F., Schwartz H., et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol. 2000 Nov;95 (11):3112-7.

Lanza F., Sahba B., et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. 2002 Jan;97 (1):58-64.

Lekkerkerker F., Kanis J.A., Alsayed N., et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 18:1311-1317.

Marshall J.K. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf. 2002 May;1 (1):71-8.

Marshall J.K., Thabane M., James C. Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. Dig Dis Sci., 2006, May;51 (5):864-8. Epub 2006 Apr 27.

Miller P.D., Woodson G., Licata A.A., et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000 Dec;22 (12):1433-42.

NICE Technology Appraisal 87 January 2005 Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. www.nice.org.uk <http://www.nice.org.uk>.

Penning-van Beest F.J., Goettsch W.G., Erkens J.A., Herings R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006 Feb;28 (2):236-42. Penning-van Beest F.J., Erkens J.A., Olson M., Herings R.M. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2007 Sep 14; [Epub ahead of print]

Purcell P.M., Boyd I.W. «Bisphosphonates and osteonecrosis of the jaw.» Medical Journal of Australia, 2005, 182 (8), 417-8.

Ringe J.D., Christodoulakos G.E. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin. 2007 Sep 19; [Epub ahead of print]

Rossini M., Bianchi G., Di Munno O., et al.; Treatment of Osteoporosis in clinical Practice (TOP) Study Group Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17 (6):914-21.

Sambrook P. Once weekly alendronate. Drugs Today (Barc), 2003 May;39 (5):339-46.

Sener G., Goren F.O., Ulusoy N.B., et al. Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. Dig Dis Sci., 2005, Aug;50 (8):1506-12.

Sener G., Sehirli O., Cetinel S., et al. Protective effect of taurine against alendronate-induced gastric damage in rats. Fundam Clin Pharmacol.,2005,Feb;19 (1):93-100.

Simon J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002 Nov;24 (11):1871-86.

Simon L.S., Lanza F.L., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum, 1998, Sep; 41 (9): 1591-602.

Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. The Journal of Rheumatology, 1999, V6, S56.

Solomon D.H., Avorn J., Katz et al. Compliance with osteoporosis indications. Arch Intern Med,2005, 165:2414-2419

Unson C.G., Siccion E., Gaztambide J., et al. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003 Dec;12 (10):1037-45.

Watts N., Freedholm D., Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract Suppl. 1999 Apr;101:51-61.

Weiss M., Vered I., Foldes A.J., Cohen Y.C., Shamir-Elron Y., Ish-Shalom S.; Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res. 2005 Apr;17 (2):143-9.

Weycker D., Macarios D., Edelsberg J. et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int,2006, 17:1645-1652

The authors declare that there are no conflicts of interest present.